Veracyte News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

11.05.17	Data Demonstrating Cost-Effectiveness of Veracyte's Percepta® Bronchial Genomic Classifier Published in "Journal of Thoracic Oncology" (PR Newswire)
10.05.17	Veracyte Announces Six Studies Highlighting Value of Company's Genomic Classifiers in Lung Cancer and Idiopathic Pulmonary Fibrosis To Be Presented at ATS 2017 (PR Newswire)
08.05.17	Data Presented at AACE 2017 Annual Meeting Demonstrate Long-Term Clinical Utility Of Veracyte's Afirma® Gene Expression Classifier in Thyroid Cancer Diagnosis (PR Newswire)
04.05.17	Veracyte Announces Pivotal Clinical Validation Data for Next-Generation Afirma® Test To Help More Patients Avoid Unnecessary Surgery in Thyroid Cancer Diagnosis (PR Newswire)
03.05.17	Veracyte Announces First Quarter 2017 Financial Results (PR Newswire)
19.04.17	Veracyte to Host Conference Call and Webcast to Discuss First Quarter 2017 Financial Results on Wednesday, May 3, 2017 (PR Newswire)
03.04.17	Multiple Studies Presented at ENDO 2017 Support Use of Veracyte's Afirma® Gene Expression Classifier In Thyroid Cancer Diagnosis (PR Newswire)
23.03.17	Veracyte Announces that Multiple Studies Supporting Clinical Utility of Its Afirma® Gene Expression Classifier To Be Presented at ENDO 2017 (PR Newswire)
01.03.17	Veracyte Announces Fourth Quarter and Full-Year 2016 Financial Results, Provides 2017 Financial Outlook (PR Newswire)
28.02.17	Veracyte Announces Executive Promotions (PR Newswire)
27.02.17	Veracyte Announces Publication of Data Demonstrating Potential for Non-Invasive Nasal Test to Improve Lung Cancer Diagnosis (PR Newswire)
21.02.17	Veracyte Announces Ten New Blues Plan Coverage Policies for Its Afirma® Gene Expression Classifier for Use in Thyroid Cancer Diagnosis (PR Newswire)
15.02.17	Veracyte to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2016 Financial Results on Wednesday, March 1, 2017 (PR Newswire)
08.02.17	Veracyte to Expand Patient Access to the Afirma® Gene Expression Classifier In Thyroid Cancer Diagnosis Through Agreement with Quest Diagnostics (PR Newswire)
06.02.17	Veracyte Announces Final Medicare Coverage Policies for Percepta® Bronchial Genomic Classifier (PR Newswire)
02.02.17	Veracyte to Present at LEERINK Partners 6th Annual Global Healthcare Conference (PR Newswire)
13.12.16	Veracyte Announces Appointment of Kevin K. Gordon and Other Changes to Its Board of Directors (PR Newswire)
22.11.16	Veracyte Announces that CMS Will Maintain Historic Medicare Reimbursement Rate for the Afirma® Gene Expression Classifier in 2017 (PR Newswire)
21.11.16	Veracyte Appoints Keith Kennedy as Chief Financial Officer (PR Newswire)
18.10.16	XENT Breathes Easy, PTCT Suffers Translarna Snub, RTTR To Report Data In Q1 (RTTNews)
03.10.16	DEPO Wins Patent Suit, EBS Surges On BARDA Funding, REGN's Eylea Combo Fails (RTTNews)
28.09.15	Veracyte Issues Statement On CMS's Preliminary 2016 Clinical Labs Fee Schedule (RTTNews)
15.04.15	MRK, NLNK Strive For Ebola Shot, VCYT Cuts A Deal, EVOK Hits Milestone (RTTNews)
17.09.14	Veracyte, Inc. Promotes Christopher Hall To COO - Quick Facts (RTTNews)
05.09.14	REPH Implodes, MRK's Keytruda Gets FDA Nod, New Entrant In Ebola Drug Study (RTTNews)
05.09.14	Veracyte To Buy Allegro Diagnostics For $21 Mln (RTTNews)
18.03.14	Veracyte Q4 Loss Widens (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Veracyte Inc

Aktien Top/Flop

Meistgelesene Nachrichten